Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: When should they be considered and which questions remain open?;Neue Strahlentherapietechniken für Involved-Field- und Involved-Node-Behandlung des mediastinalen Hodgkin-Lymphoms: Wann sollten sie in Betracht gezogen werden und welche Fragen sind noch offen?

Strahlentherapie und Onkologie

Volumn 190, Issue 10, 2014, Pages 864-871

  Lohr, Frank ^a   Georg, Dietmar ^b   Cozzi, Luca ^c   Eich, Hans Theodor ^d   Weber, Damien C ^e   Koeck, Julia ^a   Knäusl, Barbara ^b   Dieckmann, Karin ^b   Abo Madyan, Yasser ^a   Fiandra, Christian ^f   Mueller, Rolf Peter ^g   Engert, Andreas ^g   Ricardi, Umberto ^f  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Hodgkin lymphoma; Intensity modulated radiotherapy; Involved field; Involved node; Proton therapy

Indexed keywords

ALGORITHM; BREATHING FREQUENCY MONITOR; CANCER RISK; CONTROLLED STUDY; DOSIMETRY; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INVOLVED FIELD RADIOTHERAPY; METASTASIS; ORGANS AT RISK; PATIENT CODING; PROTON THERAPY; RADIOTHERAPY; REVIEW; THREE DIMENSIONAL RADIOTHERAPY; TREATMENT OUTCOME; COMPUTER ASSISTED RADIOTHERAPY; EVIDENCE BASED MEDICINE; GERMANY; LYMPH NODE; MEDIASTINAL NEOPLASMS; ONCOLOGY; PRACTICE GUIDELINE; PROCEDURES; RADIATION RESPONSE; STANDARDS;

EVIDENCE-BASED MEDICINE; GERMANY; HODGKIN DISEASE; HUMANS; LYMPH NODES; MEDIASTINAL NEOPLASMS; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 84915814245     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0719-9     Document Type: Review

References (60)

1. Andolino DL, Hoene T, Xiao L et al (2011) Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin’s lymphoma in female pediatric patients. Int J Radiat Oncol Biol Phys 81:e667–e671
2. Behringer K, Josting A, Schiller P et al (2004) Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 15:1079–1085
3. Berrington de Gonzalez A, Gilbert E, Curtis R et al (2013) Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys 86:224–233
4. Bert C, Richter D, Durante M et al (2012) Scanned carbon beam irradiation of moving films: comparison of measured and calculated response. Radiat Oncol 7:55
5. Brodin NP, Maraldo MV, Aznar MC et al (2014) Interactive decision-support tool for risk-based radiation therapy plan comparison for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 88:433–445
6. Campbell BA, Hornby C, Cunninghame J et al (2012) Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 23:1259–1266
7. Campbell BA, Voss N, Pickles T et al (2008) Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 26:5170–5174
8. Cella L, Conson M, Pressello MC et al (2013) Hodgkin’s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms. Radiat Oncol 8:22
9. Chera BS, Rodriguez C, Morris CG et al (2009) Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin’s lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 75:1173–1180
10. Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998
11. De Bruin ML, Sparidans J, van’t Veer MB et al (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27:4239–4246
12. De Sanctis V, Bolzan C, D’Arienzo M et al (2012) Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy? Radiat Oncol 7:129
13. Dorr W, Herrmann T (2008) Second tumors after oncologic treatment. Strahlenther Onkol 184:67–72
14. Eich HT, Diehl V, Gorgen H et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199–4206
15. Eich HT, Kriz J, Muller RP (2011) Evolution of radiation therapy within the German Hodgkin Study Group trials. J Natl Compr Canc Netw 9:1073–1080
16. Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410
17. Fiandra C, Filippi A, Catuzzo P et al (2012) Different IMRT solutions vs. 3D-Conformal Radiotherapy in Early Stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 7:186
18. Filippi AR, Ragona R, Fusella M et al (2013) Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Practical Radiation Oncology 3:216–222
19. Franklin J, Pluetschow A, Paus M et al (2006) Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol 17:1749–1760
20. Gagliardi G, Constine LS, Moiseenko V et al (2010) Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 76:77–85
21. Girinsky T, Pichenot C, Beaudre A et al (2006) Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 64:218–226
22. Girinsky T, Specht L, Ghalibafian M et al (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202–210
23. Glanzmann C, Veraguth A, Lutolf UM (1994) Incidence of second solid cancer in patients after treatment of Hodgkin’s disease. Strahlenther Onkol 170:140–146
24. Hall EJ (2006) Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65:1–7
25. Hodgson DC, Koh ES, Tran TH et al (2007) Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110:2576–2586
26. Hoppe BS, Flampouri S, Su Z et al (2012) Effective Dose Reduction to Cardiac Structures Using Protons Compared With 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 84:449–455
27. Hoppe BS, Flampouri S, Su Z et al (2011) Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study. Int J Radiat Oncol Biol Phys 83:260–267
28. Jang SY, Liu HH, Mohan R (2008) Underestimation of low-dose radiation in treatment planning of intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 71:1537–1546
29. Keilholz L, Willner J, Thiel HJ et al (2014) Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer: the DEGRO-QUIRO trial. Strahlenther Onkol 190:17–25
30. Knäusl B, Lütgendorf-Caucig C, Hopfgartner J et al (2013) Can treatment of Paediatric Hodgkin’s Lymphoma be improved by PET imaging and proton therapy? Strahlenther Onkol 189:54–61
31. Koeck J, Abo-Madyan Y, Eich HT et al (2012) Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin’s disease. Strahlenther Onkol 188:653–659
32. Koeck J, Abo-Madyan Y, Lohr F et al (2012) Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys; 83:268–276
33. Koelbl O, Krieger T, Haedinger U et al (2004) Influence of calculation algorithm on dose distribution in irradiation of non-small cell lung cancer (NSCLC) collapsed cone versus pencil beam. Strahlenther Onkol 180:783–788
34. Li J, Dabaja B, Reed V et al (2011) Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys 81:167–174
35. Lohr F, El-Haddad M, Dobler B et al (2009) Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality. Int J Radiat Oncol Biol Phys 74:73–80
36. Lütgendorf-Caucig C, Fotina I Gallop-Evans E, et al (2013) Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin’s lymphoma. A case study. Strahlenther Onkol 188:1025–1030
37. Meyer RM, Gospodarowicz MK, Connors JM et al (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366:399–408
38. Moskowitz CS, Chou JF, Wolden SL et al (2012) New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: a report from the Childhood Cancer Survivor Study (CCSS) and the Women’s Environmental Cancer and Radiation Epidemiology (WECARE) Study. J Clin Oncol 30
39. Newhauser WD, Durante M (2011) Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer 11:438–448
40. Nieder C, Schill S, Kneschaurek P et al (2007) Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol 2:20
41. Nilsson G, Holmberg L, Garmo H et al (2012) Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol 30:380–386
42. Paganetti H (2012) Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys Med Biol 57:R99–117
43. Paganetti H, Athar BS, Moteabbed M et al (2012) Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field. Phys Med Biol 57:6047–6061
44. Paumier A, Ghalibafian M, Gilmore J et al (2012) Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 82:1522–1527
45. Paumier A, Khodari W, Beaudre A et al (2012) Intensity-modulated radiotherapy and involved-node concept in patients with Hodgkin lymphoma: experience of the Gustave-Roussy Institute. Cancer Radiother 15:709–715
46. Pierce DA, Shimizu Y, Preston DL et al (2012) Studies of the mortality of atomic bomb survivors. report 12, part I. Cancer: 1950–1990. Radiat Res 178:AV61–87
47. Pommier P, Dussart S, Girinsky T et al (2011) Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study. Int J Radiat Oncol Biol Phys 79:823–828
48. Rombi B, DeLaney TF, MacDonald SM et al (2012) Proton radiotherapy for pediatric Ewing’s sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys 82:1142–1148
49. Schneider U, Lomax A, Pemler P et al The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlenther Onkol 182:647–652
50. Shahidi M, Kamangari N, Ashley S et al (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78:1–5
51. Sharma S, Ott J, Williams J et al (2011) Dose calculation accuracy of the Monte Carlo algorithm for CyberKnife compared with other commercially available dose calculation algorithms. Med Dosim 36:347–350
52. Slanina J, Heinemann F, Henne K et al (1999) [Second malignancies after the therapy of Hodgkin’s disease: the Freiburg collective 1940–1991]. Strahlenther Onkol 175:154–161
53. Smalley SR, Benedetti JK, Haller DG et al (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase iii trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327–2333
54. Specht L, Yahalom J, Illidge T et al (2014) Modern radiation therapy for hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862
55. Vorwerk H, Zink K, Schiller R et al (2014) Protection of quality and innovation in radiation oncology: the prospective multicenter trial the German Society of Radiation Oncology (DEGRO-QUIRO study). Evaluation of time, attendance of medical staff, and resources during radiotherapy with IMRT. Strahlenther Onkol 190:433–443
56. Weber DC, Johanson S, Peguret N et al (2011) Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 81:490–497
57. Weber DC, Peguret N, Dipasquale G et al (2009) Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 75:1578–1586
58. Weber DC, Trofimov AV, Delaney TF et al (2004) A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. Int J Radiat Oncol Biol Phys 58:1596–1606
59. Wolden SL, Lamborn KR, Cleary SF et al (1998) Second cancers following pediatric Hodgkin’s disease. J Clin Oncol 16:536–544
60. Zelefsky MJ, Pei X, Teslova T et al (2012) Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int 110:1696–1701